#SFHU2613531SFrance Adds Cadmium Testing and Cardiomyopathy Gene Sequencing to Covered Health Services
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This decision adds new medical biology tests to the list of services covered by French health insurance. It creates reimbursable urine and blood cadmium tests for people who may be overexposed because they live in areas officially identified as cadmium-polluted, and for patients being monitored for chronic cadmium poisoning. It also adds targeted high-throughput gene sequencing for diagnosing hypertrophic cardiomyopathies when a hereditary heart condition is suspected after initial clinical assessment. Medical laboratories, prescribers, cardiology teams, genetics teams, and affected patients should check the new test conditions and coding rules.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Creates a covered urine cadmium test for screening and monitoring people exposed through residence in officially identified polluted areas
- Creates a covered whole-blood cadmium test to be used when urine cadmium results are elevated
- Adds targeted gene panel sequencing for diagnosis of suspected hereditary hypertrophic cardiomyopathy
Obligations
What this law requires
Perform urinary cadmium testing (cadmiurie, act 1692) as a first-line test only for screening people potentially overexposed to cadmium because they live on sites whose soil has been officially recognized by competent authorities as cadmium-polluted, or for monitoring patients with chronic cadmium poisoning linked to their place of residence.
Express urinary cadmium test results in micrograms per gram of creatinine, with urinary cadmium concentration adjusted to creatinine concentration.
Carry out urinary cadmium testing under the conditions defined by HAS Opinion No. 2024.0061/AC/SEAP of 26 September 2024.
Perform whole-blood cadmium testing (cadmiémie, act 1693) only as a complementary test where urinary cadmium testing is elevated, for the same residence-related screening or chronic cadmium poisoning monitoring indications.
Carry out whole-blood cadmium testing under the conditions defined by HAS Opinion No. 2024.0061/AC/SEAP of 26 September 2024.